Analyst Research Report Snapshot

Title:

Transgenomic, Inc.

Price:

$50.00

Provider:

MarketLine (a Datamonitor Company)

Date:

26 Nov 2013

Pages:

41

Type:

AcrobatPDF

Companies referenced:

TBIO.PK

Available for Immediate Download
Summary:

Transgenomic, Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Transgenomic, Inc. required for business and competitor intelligence needs - Intelligence on Transgenomic, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Transgenomic, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Transgenomic is a biotechnology company that provides products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. The company also provides laboratory services to molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Its product offerings include the WAVE Systems, SURVEYOR mutation detection kits, equipment, reagents and other associated consumables designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. The company primarily operates in the US, Italy, Germany, France, Netherlands and the UK. It is headquartered in Omaha, Nebraska and employs around 162 people. The company recorded revenues of $20 million in the fiscal year ended December 2010, a decrease of 9% compared to 2009. The company's operating loss was $3.6 million in fiscal 2010, as compared to an operating loss of $1.9 million in 2009. Its net loss was $3.1 million in fiscal 2010, as compared to the net loss of $1.9 million in 2009. Reasons to Purchase: - Gain understanding of Transgenomic, Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Transgenomic, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Transgenomic, Inc. your competitors' business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.